China Needs To Balance Equal Access To Affordable Medicines With Sharpening Focus On Innovative Drugs In Mapping Out Future, Say Leaders At DIA Conference
This article was originally published in PharmAsia News
Executive Summary
BEIJING - As China launches sweeping health system reforms in phases over the next decade, the country must balance competing interests in mapping out the future: laying the groundwork for affordable and ultimately universal coverage while promoting the development of research- and capital-intensive innovative medicines, according to drug industry, academic and policy-making leaders who provided glimpses of the road ahead during the second annual meeting of the Drug Information Association in China
You may also be interested in...
China's Health Reform Will Nurture New Drugs, While Boosting Use Of Old Ones - PharmAsia Summit
SAN FRANCISCO - In addition to dramatically increasing access to mainly generic drugs, China's sweeping and upcoming health reform will also include measures designed to spur R&D, according to Song Ruilin, Executive Director-General at the Chinese Pharmaceutical Association's Research Center for Medicinal Policy
China Paring Down Essential Medicines List In Sweeping Health System Reforms
[Editor's note: This is part three in a new series on China's wide-ranging plans to reform the country's health system, including its hospitals, insurance schemes, and access to medicines. Part one in the series appeared in PharmAsia News Oct. 30, 2008, and part two appeared Nov. 13, 2008.]
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).